pp-266 Tablets
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Cancer, Graft versus host disease, Hematological disease, Neoplasm
Clinical stage: Phase 2
Modality: Small molecule inhibitor
Mechanism & Target: Immunomodulator, Anticancer protein kinase inhibitor, Anticancer multidrug resistance inhibitor, Anticancer chemosensitizer
Route & form: Oral
Differentiation: it is a triple inhibitor of Axl, Mer, and CSF1R, showing promise for the treatment of AML and chronic graft-versus-host disease (cGVHD).
Manufacturer #39679
A clinical-stage biopharmaceutical company focused on oncology. Developing a small molecule therapeutic targeting oncology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None